| Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes |
|
Annals of internal medicine |
Myelodysplastic Syndromes (MDS) |
| Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria |
|
Expert Opinion on Pharmacotherapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria |
|
Expert Opinion on Pharmacotherapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria |
|
Journal of Managed Care & Specialty Pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria |
|
Blood |
Aplastic Anemia |
| iPSC-derived modeling of HLA-lacking hematopoiesis reveals clonal diversity in eltrombopag response in acquired aplastic anemia |
|
Stem Cells |
Aplastic Anemia |
| Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Initial management of patients with acquired aplastic anemia in the United States: results from a large national claims database |
|
Annals of Hematology |
Aplastic Anemia |
| Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
